- The round was led by Axil Capital Partners, with participation from Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC
- Luca Science is a preclinical biopharmaceutical company focusing on the discovery of novel mitochondria therapy to treat diseases and injuries in multiple therapeutic areas
- Mitochondria are the power plants in human cells that produce energy for human bodies
- These small intracellular organelles house cellular aerobic respiration, the process also used to turn oxygen and nutrients into energy
- Then the company is developing an innovative platform of highly functional mitochondrial using proprietary technologies
- Its mitochondria can stored and delivered as a biopharmaceutical agent
